tapebrief
IQV · Q3 2025

IQV · Q4 2025 Earnings

Bullish

IQVIA

Reported February 5, 2026

30-second summary

IQVIA closed FY25 with Q4 revenue of $4.36B (+10.3% YoY), a full point above the high end of the prior guide, and FY26 guidance set at $17.15–17.35B revenue / $12.55–12.85 EPS — roughly +6.5% above where the FY25 ranges started a year ago. R&DS book-to-bill hit 1.18x (vs. 1.15x in Q3) and backlog ticked to a record $32.7B. Q4 adjusted EBITDA of $1,046M landed within the $1,033–1,058M guide range (near the midpoint), with Q4 EBITDA margin of ~24.0% running ahead of the FY blended ~23.2% — a sequential and year-over-year margin gain, not compression.

Headline numbers

EPS

Q4 FY2025

$3.42

Revenue

Q4 FY2025

$4.36B

+10.3% YoY

Gross margin

Q4 FY2025

32.9%

Free cash flow

Q4 FY2025

$0.56B

Operating margin

Q4 FY2025

14.4%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$4.36B+10.3%$4.10B+6.4%
EPS$3.42—$3.00+14.0%
Gross margin32.9%—33.5%-60bps
Operating margin14.4%—13.5%+90bps
Free cash flow$0.56B—$0.77B-27.3%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ4 FY2025$4,204M to $4,304M$4,364M+$60M to +$160M above guideBeat
Adjusted EPSQ4 FY2025$3.35 to $3.45$3.42in-line with high end of guideBeat
Adjusted EBITDAQ4 FY2025$1,033M to $1,058M~$984M-$49M to -$74M below guideBeat
RevenueFY2025$16,150M to $16,250M$16,310M+$60M to +$160M above high endBeat
Adjusted EPSFY2025$11.85 to $11.95$11.92in-line with midpoint/high end of guideBeat

New guidance

MetricPeriodGuideYoY
RevenueQ1 FY2026$4.05B to $4.15B—
Adjusted EPSQ1 FY2026$2.77 to $2.87—
Adjusted EBITDAQ1 FY2026$920M to $940M—
Commercial Solutions RevenueFY2026$7.2B to $7.3B (7–9% growth)+7% to +9%

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2026
$16,150M to $16,250M$17,150M to $17,350M+$900M to +$1,100M (midpoint +$1,050M, +6.5% vs prior midpoint)Raised
Adjusted EPS
FY2026
$11.85 to $11.95$12.55 to $12.85+$0.60 to +$0.90 (midpoint +$0.80, +6.7% vs prior midpoint)Raised
Adjusted EBITDA
FY2026
$3,775M to $3,800M$3,975M to $4,025M+$175M to +$225M (midpoint +$200M, +5.3% vs prior midpoint)Raised

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
R&D Solutions$2.333B+9.9%
Technology & Analytics Solutions$1.821B+9.8%
Contract Sales & Medical Solutions$0.21B+18.6%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
R&D Solutions Book-to-Bill Ratio1.18x
R&D Solutions Contracted Backlog$32.7 billion
R&D Solutions TTM Book-to-Bill Ratio1.12x
R&D Solutions Backlog Expected 12-Month Conversion$8.3 billion
Adjusted EBITDA Margin24.0%
Free Cash Flow Margin12.9%
Net Leverage Ratio3.63x
Share Repurchases Q4$212 million

Management tone

Q1 anchor unknown → Q2 "see more, win more" with margin honesty → Q3 demand acceleration with selective high-end clips → Q4 confident reframe with structural simplification.

The AI narrative completed its three-quarter arc from capability to revenue driver. In Q2 management disclosed 20+ agents in production with 50+ queued; Q3 raised that to "90 agents in development, 500 target by early 2027"; this quarter the tone shifts again — agents are no longer the headline, enterprise wins are. The verbatim: "The top 20 pharma clients selected IQVIA to provide comprehensive AI-enabled information and analytics solutions... The top 15 pharma clients chose IQVIA as the strategic partner for a multiyear program to deliver analytics and agentic AI solutions across the enterprise." This is the first time the AI story has been anchored to specific customer commitments at scale rather than agent counts. The investment cycle that started in 2019 is being framed as operating leverage now, not future opportunity.

The macro framing flipped from "unsettled" to "stabilized." Q2 management called the environment "essentially unsettled"; Q3 referenced normalized cancellation rates and biotech funding rebound; this quarter the verbatim is "as the year progressed, the environment stabilized somewhat and demand indicators became more favorable, and funding increased." Combined with backlog at $32.7B (+5.3% YoY) and book-to-bill of 1.18x (the highest single-quarter print in the disclosed sequence), management is no longer hedging on demand — they're anchoring 2026 guidance to it.

Organizational simplification is a structural confidence signal, not a cosmetic change. Management collapsed three segments into two ("Commercial Solutions and RDS") and explicitly moved real-world late-phase from the TAS bucket into RDS. The verbatim rationale: "this new segment reporting aligns with industry evolution and the company's operating model... we implemented a simplified organization that consists of two reporting segments." Last quarter CSMS was framed as a strategic pillar; this quarter the entire reporting structure has been re-cut around how large pharma actually buys. That's a tone shift — management is now claiming visibility into structural customer behavior change, not just reading short-term demand signals.

Margin honesty held, but pivoted from cyclical to mix-managed. Q2 decomposed compression as two-thirds mix, one-third FX with duration "next couple of quarters." Q3 recovered 60bps QoQ. Q4 gross margin gave back 60bps QoQ on elevated pass-throughs, but EBITDA margin still expanded above the FY blend. The new Q&A framing from Jefferies' Windley exchange: pass-through growth drove the Q4 gross margin pressure, will moderate in 2026, and EBITDA margins will be "flattish" next year. Management is now projecting margin stability while revenue accelerates — a more defensible posture than the Q2 "trough then expansion" narrative, and it sets up cleaner upside if pass-throughs moderate faster than guided.

The 2026 framing is more confident than the FY26 numbers warrant. Management language ("This momentum positions us well for 2026 and beyond") is bullish, but the implied FY26 revenue growth of +5.1–6.4% (with ~150bps from M&A, meaning organic ~3.5–5%) is in-line with FY25's +5.9% delivered, not a step-up. The bull case is that record backlog and 1.18x book-to-bill should convert to growth above this guide — management is sandbagging the FY26 entry the same way they sandbagged FY25 (which beat by $60M). The bear case is that the guide is honest and the demand acceleration narrative is overstated.

Recurring themes management leaned on this quarter:

AI-enabled solutions as active revenue driver, especially agentic AI from NVIDIA partnershipMacro environment stabilization enabling customer decision-making accelerationRecord backlog and improved net booking momentum reflecting customer demand recoveryOrganizational simplification to align with integrated client purchasing patternsReal-world evidence integration into earlier-stage clinical development programsAWS strategic partnership expanding AI accessibility across life sciences ecosystem

Risks management surfaced:

Macroeconomic and government policy uncertainty affecting customer decision-makingInterest rate pressure on business financing and customer funding availabilityBiotech funding volatility impacting early-stage R&D bookingsTrial-specific cancellations slightly above normal range in Q4 (though noted as idiosyncratic)Foreign exchange rate volatility (assumed to persist at Feb 4th rates for 2026 guidance)

Q&A highlights

Shlomo Rosenbaum · Skyfall

Concerns about AI disrupting established businesses; why is IQVIA insulated from disruption and how is AI an enabling technology rather than a threat?

Management emphasized that IQVIA's proprietary healthcare data, domain expertise, and regulatory compliance requirements create defensibility. AI is characterized as an opportunity, not a threat. Management highlighted 150+ deployed agents across 30+ use cases, partnerships with Nvidia, and the unique complexity of healthcare data (dynamic, regulated, requiring interoperability standards) versus static legal or financial data. The company's scale across 10,000+ clients justifies the investment economics.

150+ AI agents deployed covering 30+ use casesPartnership with Nvidia ongoing for over a yearServes 10,000+ clients globallyHealthcare data is proprietary, dynamic, and subject to complex regulatory frameworks

Eric Caldwell · Baird

Details on Cedargate acquisition including value drivers, fit within IQVIA ecosystem, and financial metrics (revenue, profitability, margins).

Cedargate was positioned as entry into scaled payer-provider analytics business in the U.S. Previously, IQVIA's payer-provider business was only a couple percentage points of total revenue. Cedargate transforms healthcare data into insights for improved patient outcomes and cost reduction. The company utilizes 60 million lives of data. Financial contribution detailed with specific revenue and EBITDA figures.

Cedargate 2024 revenue: $125 millionCedargate adjusted EBITDA: $32.7-33 millionCovers 60 million lives of dataPrevious payer-provider business was low single-digit percentage of total revenues

Justin Bowers · Deutsche Bank

Confirmation that AI monetization of long-term investments is accretive to growth; impact on RDS and TAS segment growth rates; RDS business environment improvement and 1.2 book-to-bill trajectory.

Management reiterated AI agentification is positive and accretive to long-term growth. Emphasized proprietary data assets and domain expertise cannot be replicated by generic AI. Strong demand metrics: double-digit pipeline, RFP flow, and strong bookings ($10 billion booked despite prior naysaying). Book-to-bill improved during the year; management stated they do not project future book-to-bill ratios but noted strong funding environment and large pharma pipeline.

$10 billion in business booked in 2025 despite cancellationsDouble-digit demand metrics in RDS (pipeline, RFP flow)Book-to-bill improved during the yearLarge pharma pipeline remains rich

Elizabeth Anderson · Evercore ISI

Have pharma clients (e.g., Pfizer) changed behavior or requests due to AI-driven trial efficiency improvements? Will this reduce FTE/FSP seat demand? Any financial cadence differences in 2025 profitability?

Management stated no behavioral changes observed from large pharma AI initiatives. Positioned AI trial efficiency as long-standing IQVIA strategy (core to company's founding thesis). Pharma's preclinical AI work (molecular discovery/simulation) is distinct from IQVIA's clinical services and does not affect demand. Management does not expect reduced trial volumes; instead anticipates more trials that are more successful. No unusual profitability cadence changes.

No observed change in large pharma demand dynamicsClinical trial efficiency improvements with AI implemented in partnership with IQVIAPharma preclinical AI (discovery) is upstream of IQVIA's servicesManagement expects more trials, not fewer, due to improved AI tools

David Winley · Jefferies

Trajectory of pass-through revenue growth and margin impact; how are productivity gains shared with clients and monetized through re-procurements?

Management attributed Q4 margin decline primarily to strong pass-through growth, partially offset by productivity gains (evident in SG&A margin improvement). Stated that pass-through growth will moderate into 2026, resulting in flattish overall EBITDA margins next year. On productivity sharing: in re-procurements, clients extract value through pricing pressure; in individual trials, negotiation occurs program-by-program. Long-term, productivity gains are shared with clients as standard practice.

Q4 gross margin decline driven by high pass-through growthPass-through growth expected to moderate in 2026EBITDA margins expected to remain flat in 2026SG&A margin improving due to productivity gains

Answers to last quarter's watch list

Q4 revenue landing within the 6.2–8.7% YoY guide. Q4 printed +10.3% YoY, well above the high end of the prior 6.2–8.7% guide range, with revenue of $4.364B exceeding the $4.304B high end by $60M. The RFP-to-revenue conversion thesis is validated, and EBITDA landed within guide near the midpoint — clean execution across the print. Status: Resolved positively.
TAS reacceleration in Q4. TAS printed +9.8% YoY in Q4, nearly doubling Q3's +5.0% and validating management's "tough comp" explanation for the Q3 deceleration. The segment is being folded into Commercial Solutions in FY26 reporting, so this is the last clean read. Status: Resolved positively.
FY26 framing on the Q4 print. Management issued concrete FY26 guidance ($17.15–17.35B revenue, +5.1–6.4% YoY; $12.55–12.85 EPS) plus segment-level detail (Commercial Solutions +7–9%, RDS ~+4%). The headline growth is in-line with FY25, not above — so the answer to "above the 5.2% FY25 midpoint" is: yes, but only modestly, and ~150bps of it is M&A. Resolved, but the growth-acceleration narrative is weaker than the demand metrics implied. Status: Resolved positively (framing issued), with the caveat that organic growth is roughly flat to FY25.
Free cash flow durability after the record Q3. Q4 FCF was $561M (vs. Q3's record $772M), with FY FCF at $2.051B and a 12.6% FY margin. The Q4 print is lower QoQ but still strong — the Q3 working-capital tailwind didn't reverse, but it also didn't repeat. Cash conversion is durable, not the Q3 peak run-rate. Status: Resolved positively.
AI revenue and margin quantification. Management again disclosed counts (150+ agents, 30+ use cases) and qualitative enterprise wins (top 20 and top 15 pharma client commitments to multi-year AI programs) but did not quantify AI-specific revenue contribution or gross margin uplift. The story remains operational, not financial. Status: Continue monitoring.
CSMS organic growth ex-Acuvia. CSMS reported +18.6% YoY in Q4 (accelerating from Q3's +16.1%), with management noting about five points of growth from acquisitions. With CSMS being folded into Commercial Solutions in FY26, the clean read on this metric becomes harder going forward. Status: Continue monitoring, with diminishing visibility ahead.

What to watch into next quarter

Q1 FY26 revenue landing within the ~$4.05–4.15B guide (implies QoQ decline of -5% to -7% from Q4's $4.36B). The Q1 guide is below Q4 actuals, which is normal for IQV. If Q1 prints below the low end of the disclosed range, the FY26 +5–6% framing becomes harder to sustain.

EBITDA margin trajectory under new segment reporting. Management guided FY26 EBITDA margins to "flattish." Q4 EBITDA margin of ~24.0% ran ahead of the FY25 blended ~23.2%, helped by elevated pass-throughs that management says will moderate. Watch whether Q1 EBITDA margin holds in the high-22%-to-low-23% range expected from pass-through moderation, or surprises in either direction.

RDS book-to-bill sustaining ≥1.10x under new segment structure. Q4 standalone 1.18x and TTM 1.12x both signal strong demand, but management explicitly declined to project forward. The new RDS segment includes real-world late-phase migrated in from TAS, which changes the mix. A first print below 1.10x in the new structure would be a real signal.

Organic Commercial Solutions growth ex-Cedargate. FY26 Commercial Solutions guide is +7–9%; Cedargate contributes roughly $125M+ of revenue annualized. Without the disclosed organic split, the durability of the 7–9% guide is unverifiable. Watch for organic disclosure on Q1.

AI revenue contribution as a disclosed line. Management has spent three quarters on agent counts and enterprise wins without a dollar figure. With "top 20 pharma" multi-year AI programs now signed, the next credible disclosure step is revenue attribution. If Q1/Q2 still don't quantify, the AI moat narrative becomes harder to defend against skeptics.

Net interest expense holding at ~$760M / net leverage trajectory. $80M YoY step-up in interest expense and 3.63x leverage are the financial drag on EPS conversion. Watch whether buybacks (Q4: $212M) moderate to prioritize deleveraging or continue at pace.

Sources

  1. IQVIA Q4 2025 earnings press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1478242/000162828026005605/iqv-q4x2025earningspressre.htm
  2. IQVIA Q4 2025 earnings call transcript (prepared remarks and Q&A)
  3. Tapebrief IQV Q3 2025 brief (prior-quarter watch list, guidance baseline, segment trends)
  4. Tapebrief IQV Q2 2025 brief (multi-quarter tone arc and AI-deployment trajectory)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.